Form 4: Abeona Therapeutics Director Leila Alland Acquires Shares as Part of Annual Grant

Director Leila Alland acquired 11,797 shares of Abeona Therapeutics common stock as part of the remainder of the 2024 annual grant to the board of directors.

Summary

• On August 26, 2024, Leila Alland, a director of Abeona Therapeutics Inc., acquired 11,797 shares of common stock.
• The acquisition was part of the 2024 annual grant to the board of directors.
• This portion of the grant was withheld until all employees/management were allocated their shares and to enable onboarding of two new board members.
• The shares were acquired at a price of $0.
• Following the transaction, Alland directly owns 118,265 shares of Abeona Therapeutics common stock.
• The restricted stock will vest on August 26, 2025.

Sentiment

Score: 6

Explanation: The sentiment is neutral as it reflects a standard stock grant to a board member, with no particularly positive or negative implications.

Positives

• Director Alland's acquisition of shares reflects continued alignment with shareholder interests.
• The vesting of the restricted stock on August 26, 2025, incentivizes long-term commitment.

Future Outlook

The document does not contain forward-looking statements or guidance.

Industry Context

This Form 4 filing is a routine disclosure related to insider transactions and provides transparency to the market regarding the holdings of company directors.

Stakeholder Impact

• The transaction provides transparency to shareholders regarding director compensation and ownership.

Key Dates